Elevai Labs Inc received an extension from Nasdaq to comply with the bid price rule, allowing them to complete a reverse stock split by December 26, 2024, and demonstrate compliance by January 9, 2025. Additionally, two subsidiaries changed their names to PMGC Research Inc and Northstrive Biosciences Inc.